Management of anxiety and motor symptoms in Parkinson’s disease

References

• Dissanayaka NM, Sellbach A, Matheson S, et al. Anxiety disorders in Parkinson’s disease: prevalence and risk factors. Mov Disord 2010;25(7):838-45
   PubMed Web of Science ®Google Scholar
• Chen PH, Cheng SJ. Depression in Parkinson disease: current understanding and treatment. Int J Gerontol 2008;2(4):172-82
   Google Scholar
• Almeida QJ, Hyson HC. The evolution of pharmacological treatment for Parkinson’s disease. Recent Pat CNS Drug Discov 2008;3(1):50-4
   PubMedGoogle Scholar
• Kurtis MM, Rodriguez-Blazquez C, Martinez-Martin P. Relationship between sleep disorders and other non-motor symptoms in Parkinson’s disease. Parkinsonism Relat Disord 2013(19):12
   Google Scholar
• Aarsland D, Brønnick K, Alves G, et al. The spectrum of neuropsychiatric symptoms in patients with early untreated Parkinson’s disease. J Neurol Neurosurg Psychiatry 2009;80(8):928-30
   PubMed Web of Science ®Google Scholar
• Djamshidian A, Friedman JH. Anxiety and depression in Parkinson’s disease. Curr Treat Options Neurol 2014;16(4):285
   PubMed Web of Science ®Google Scholar
• Aarsland D, Marsh L, Schrag A. Neuropsychiatric symptoms in Parkinson’s disease. Mov Disord 2009;24(15):2175-86
   PubMed Web of Science ®Google Scholar
• Jaunarajsa KLE, Angoa-Perezb M, Kuhnb DM, Bishopa C. Potential mechanisms underlying anxiety and depression in Parkinson’s disease: consequences of L-DOPA treatment. Neurosci Biobehav Rev 2012;35(3):556-64
   Google Scholar
• Barone P, Antonini A, Colosimo C, et al. The PRIAMO study: a multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson’s disease. Mov Disord 2009;24(11):1641-9
   PubMed Web of Science ®Google Scholar
• Nègre-Pagès L, Grandjean H, Lapeyre-Mestre M, et al. Anxious and depressive symptoms in Parkinson’s disease: the French cross-sectional DoPaMiP study. Mov Disord 2010;25(2):157-66
   PubMed Web of Science ®Google Scholar
• Quelhas R, Costa M. Anxiety, depression, and quality of life in Parkinson’s disease. J Neuropsychiatry Clin Neurosci 2009;21(4):413-19
   PubMed Web of Science ®Google Scholar
• Goetz CG. New developments in depression, anxiety, compulsiveness, and hallucinations in Parkinson’s disease. Mov Disord 2010;25(Suppl 1):S104-9
   Google Scholar
• Pontone GM, Williams JR, Anderson KE, et al. Pharmacologic treatment of anxiety disorders in Parkinson disease. Am J Geriatr Psychiatry 2013;21(6):520-8
   PubMed Web of Science ®Google Scholar
• Chaudhuri KR, Schapira AH. Non-motor symptoms of Parkinson’s disease: dopaminergic pathophysiology and treatment. Lancet Neurol 2009;8(5):464-74
   PubMed Web of Science ®Google Scholar
• Pontone GM, Williams JR, Anderson KE, et al. Prevalence of anxiety disorders and anxiety subtypes in patients with Parkinson’s disease. Mov Disord 2009;24(9):1333-8
   PubMed Web of Science ®Google Scholar
• Weintraub D, Comella CL, Horn S, Care M. Parkinson’s disease- part 3: neuropsychiatric symptoms. Am J Manag Care 2008;14(2):59-69
   Google Scholar
• Prediger RD, Matheus FC, Schwarzbold ML, et al. Anxiety in Parkinson’s disease: a critical review of experimental and clinical studies. Neuropharmacology 2012;62(1):115-24
   PubMed Web of Science ®Google Scholar
• Leentjens AFG, Dujardin K, Marsh L, et al. Symptomatology and markers of anxiety disorders in Parkinson’s disease: a cross-sectional study. Mov Disord 2011;26(3):484-92
   PubMed Web of Science ®Google Scholar
• Kano O, Ikeda K, Cridebring D, et al. Neurobiology of depression and anxiety in Parkinson’s disease. Parkinsons Dis 2011;2011:1-5
   Google Scholar
• Leentjens a FG, Dujardin K, Marsh L, et al. Anxiety and motor fluctuations in Parkinson’s disease: a cross-sectional observational study. Parkinsonism Relat Disord 2012;18(10):1084-8
   PubMedGoogle Scholar
• Turner RS, Desmurget M. Basal ganglia contributions to motor control: a vigorous tutor. Curr Opin Neurobiol 2010;20(6):704-16
   PubMedGoogle Scholar
• Connolly B, Fox SH. Treatment of cognitive, psychiatric, and affective disorders associated with Parkinson’s disease. Neurotherapeutics 2014;11(1):78-91
   PubMed Web of Science ®Google Scholar
• Schneider F, Althaus A, Backes V, Dodel R. Psychiatric symptoms in Parkinson’s disease. Eur Arch Psychiatry Clin Neurosci 2008;258(Suppl 5):55-9
   PubMedGoogle Scholar
• Gallagher DA, Lees AJ, Schrag A. What are the most important nonmotor symptoms in patients with Parkinson’s disease and are we missing them? Mov Disord 2010;25(15):2493-500
   PubMed Web of Science ®Google Scholar
• Riedel O, Klotsche J, Spottke A, et al. Frequency of dementia, depression, and other neuropsychiatric symptoms in 1,449 outpatients with Parkinson’s disease. J Neurol 2010;257(7):1073-82
   PubMed Web of Science ®Google Scholar
• Tan LC. Mood disorders in Parkinson’s disease. Parkinsonism Relat Disord 2012;18(1):74-6
   Google Scholar
• Kummer A, Cardoso F, Teixeira AL. Generalized anxiety disorder and the Hamilton Anxiety Rating Scale in Parkinson’s disease. Arq Neuropsiquiatr 2010;68(4):495-501
   PubMedGoogle Scholar
• Poewe W. Non-motor symptoms in Parkinson’s disease. Euro J Neuro 2008;15(1):14-20
   Google Scholar
• Zesiewicz TA, Sullivan KL, Arnulf I, et al. Practice Parameter: treatment of nonmotor symptoms of Parkinson disease: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2010;74(11):924-31
   PubMed Web of Science ®Google Scholar
• Gallagher DA, Schrag A. Psychosis, apathy, depression and anxiety in Parkinson’s disease. Neurobiol Dis 2012;46(3):581-9
   PubMed Web of Science ®Google Scholar
• Truong DD, Bhidayasiri R, Wolters E. Management of non-motor symptoms in advanced Parkinson disease. J Neurol Sci 2008;266(1-2):216-28
   PubMed Web of Science ®Google Scholar
• Chen JJ, Marsh L. Anxiety in Parkinson’s disease: identification and management. Ther Adv Neurol Disord 2014;7(1):52-9
   PubMed Web of Science ®Google Scholar
• Spampinato MV, Wood JN, De Simone V, Grafman J. Neural correlates of anxiety in healthy volunteers: a voxel-based morphometry study. J Neuropsychiatry Clin Neurosci 2009;21(2):199-205
   PubMed Web of Science ®Google Scholar
• Paulesu E, Sambugaro E, Torti T, et al. Neural correlates of worry in generalized anxiety disorder and in normal controls: a functional MRI study. Psychol Med 2010;40(1):117-24
   PubMedGoogle Scholar
• Rabinak CA, Nirenberg MJ. Dopamine agonist withdrawal syndrome in Parkinson disease. Arch Neurol 2010;67(1):58-63
   PubMedGoogle Scholar
• Pasman EP, Murnaghan CD, Bloem BR, Carpenter MG. Balance problems with Parkinson’s disease: are they anxiety-dependent? Neuroscience 2011;177:283-91
   PubMed Web of Science ®Google Scholar
• Lemke MR. Depressive symptoms in Parkinson’s disease. Euro J Neuro 2008;15(1):21-5
   Google Scholar
• Lemke MR. Dopamine agonists in the treatment of non-motor symptoms of Parkinson’s disease: depression. Euro J Neuro 2008;15(2):9-14
   Google Scholar
• Fox SH, Chuang R, Brotchie JM. Serotonin and Parkinson’s disease: on movement, mood, and madness. Mov Disord 2009;24(9):1255-66
   PubMed Web of Science ®Google Scholar
• Thobois S, Ardouin C, Lhommée E, et al. Non-motor dopamine withdrawal syndrome after surgery for Parkinson’s disease: predictors and underlying mesolimbic denervation. Brain 2010;133(4):1111-27
   PubMedGoogle Scholar
• Savica R, Rocca W, Ahlskog JE. When does Parkinson disease start? Arch Neurol 2010;67(7):798-801
   PubMedGoogle Scholar
• Jankovic J, Aguilar LG. Current approaches in the treatment of Parkinson disease. Neuropsychiatr Dis Treat 2008;80(12):686-91
   Google Scholar
• Bezard E, Fernagut PO. Premotor parkinsonism models. Parkinsonism Relat Disord 2014;20(1):17-19
   PubMedGoogle Scholar
• Bhidayasiri R, Truong DD. Therapeutic strategies for nonmotor symptoms in early Parkinson’s disease: the case for a higher priority and stronger evidence. Parkinsonism Relat Disord 2012;18(1):S110-13
   PubMedGoogle Scholar
• Bower JH, Grossardt BR, Maraganore DM, et al. Anxious Personality Predicts an Increased Risk of Parkinson’s Disease. Mov Disord 2011;25(13):2105-13
   Google Scholar
• Jacob EL, Gatto NM, Thompson A, et al. Occurrence of depression and anxiety prior to Parkinson’s disease. Parkinsonism Relat Disord 2010;16(9):576-81
   PubMed Web of Science ®Google Scholar
• Plotnik M, Dagan Y, Gurevich T, et al. Effects of cognitive function on gait and dual tasking abilities in patients with Parkinson’s disease suffering from motor response fluctuations. Exp Brain Res 2011;208(2):169-79
   PubMed Web of Science ®Google Scholar
• Kummer A, Teixeira AL. Neuropsychiatry of Parkinson’s disease. Arq Neuropsyqiatr 2009;67(3):930-9
   PubMedGoogle Scholar
• Bayulkem K, Lopez G. Nonmotor fluctuations in Parkinson’s disease: clinical spectrum and classification. J Neurol Sci 2010;289(1-2):89-92
   PubMed Web of Science ®Google Scholar
• Maetzler W, Liepelt I, Berg D. Progression of Parkinson’s disease in the clinical phase: potential markers. Lancet Neurol 2009;8(12):1158-71
   PubMed Web of Science ®Google Scholar
• Witt K, Daniels C, Reiff J, et al. Neuropsychological and psychiatric changes after deep brain stimulation for Parkinson’s disease: a randomised, multicentre study. Lancet Neurol 2008;7(7):605-14
   PubMed Web of Science ®Google Scholar
• Pandya M, Kubu CS, Giroux ML. Parkinson disease: not just a movement disorder. Cleve Clin J Med 2008;75(12):856-64
   PubMedGoogle Scholar
• Chaudhuri KR, Odin P, Antonini A, Martinez-Martin P. Parkinson’s disease: the non-motor issues. Parkinsonism Relat Disord 2011;17(10):717-23
   PubMed Web of Science ®Google Scholar
• Park A, Stacy M. Non-motor symptoms in Parkinson’s disease. J Neurol 2009;256(Suppl 3):293-8
   PubMedGoogle Scholar
• Chen JJ, Marsh L. Depression in Parkinson’s disease: identification and management. Pharmacotherapy 2013;33(9):972-83
   PubMed Web of Science ®Google Scholar
• Fasano A, Daniele A, Albanese A. Treatment of motor and non-motor features of Parkinson’s disease with deep brain stimulation. Lancet Neurol 2012;11(5):429-42
   PubMed Web of Science ®Google Scholar
• Zibetti M, Pesare M, Cinquepalmi A, et al. Neuro-psychiatric therapy during chronic subthalamic stimulation in Parkinson’s disease. Parkinsonism Relat Disord 2009;15(2):128-33
   PubMedGoogle Scholar
• Picillo M, Rocco M, Barone P. Dopamine receptor agonists and depression in Parkinson’s disease. Parkinsonism Relat Disord 2008;15(4):81-4
   PubMedGoogle Scholar
• Jahn K, Zwergal A, Schniepp R. Gait disturbances in old age: classification, diagnosis, and treatment from a neurological perspective. Dtsch Arztebl Int 2010;107(17):306-15
   PubMed Web of Science ®Google Scholar
• Mirelman A, Herman T, Brozgol M, et al. Executive function and falls in older adults: new findings from a five-year prospective study link fall risk to cognition. PLoS One 2012;7(6):1-8
   Google Scholar
• Vandenbossche J, Deroost N, Soetens E, et al. Freezing of gait in Parkinson disease is associated with impaired conflict resolution. Neurorehabil Neural Repair 2011;25(8):765-73
   PubMedGoogle Scholar
• Troeung L, Egan SJ, Gasson N. A meta-analysis of randomised placebo-controlled treatment trials for depression and anxiety in Parkinson’s disease. PLoS One 2013;8(11):1-10
   Google Scholar
• Weintraub D, Burn DJ. Parkinson’s disease: the quintessential neuropsychiatric disorder. Mov Disord 2011;26(6):1022-31
   PubMed Web of Science ®Google Scholar
• Lopes FL, Azevedo TM, Imbiriba LA, et al. Freezing reaction in panic disorder patients associated with anticipatory anxiety. Depress Anxiety 2009;26(10):917-21
   PubMedGoogle Scholar
• Brown RG, Landau S, Hindle JV, et al. Depression and anxiety related subtypes in Parkinson’s disease. J Neurol Neurosurg Psychiatry 2011;82(7):803-9
   PubMed Web of Science ®Google Scholar
• Devos D, Dujardin K, Poirot I, et al. Comparison of desipramine and citalopram treatments for depression in Parkinson’s disease: a double-blind, randomized, placebo-controlled study. Mov Disord 2008;23(6):850-7
   PubMed Web of Science ®Google Scholar
• Fox SH, Katzenschlager R, Lim SY, et al. The movement disorder society evidence-based medicine review update: treatments for the motor symptoms of Parkinson’s disease. Mov Disord 2011;26(3):S2-41
   PubMedGoogle Scholar
• Menza M, Dobkin RD, Marin H, et al. A controlled trial of antidepressants in patients with Parkinson disease and depression. Neurology 2009;72(10):886-92
   PubMed Web of Science ®Google Scholar
• Dobkin RD, Menza M, Bienfait KL, et al. Depression in Parkinson’s disease: symptom improvement and residual symptoms after acute pharmacologic management. Am J Geriatr Psychiatry 2011;19(3):222-9
   PubMedGoogle Scholar
• Gebhardt S, Rottgers H, Backer A, et al. Treatment of panic disorder with bupropion in a patient with Parkinson’s disease. J Clin Pharm Ther 2008;33(5):575-7
   PubMedGoogle Scholar
• Politis M, Wu K, Loane C, et al. Serotonergic mechanisms responsible for levodopa-induced dyskinesias in Parkinson’s disease patients. 2014;124(3):1340-9
   Google Scholar
• Dobkin R, Menza M. Cognitive-behavioral therapy for depression in Parkinson’s disease: a randomized, controlled trial. Am J Psychiatry 2011;168(10):1066-74
   PubMed Web of Science ®Google Scholar
• Mohlman J, Reel DH, Chazin D, et al. A novel approach to treating anxiety and enhancing executive skills in an older adult with Parkinson’s disease. Clin Case Stud 2010;9(1):74-90
   PubMedGoogle Scholar